Jcr Pharmaceuticals Announces Development Plan In Japan For Givinostat For Duchenne Muscular Dystrophy
15/07/2026 24:32
BRIEF-Jcr Pharmaceuticals Co Ltd - Jcr Pharmaceuticals Announces Development Plan In Japan For Givinostat For Duchenne Muscular Dystrophy July 15 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T:
JCR PHARMACEUTICALS CO LTD: JCR PHARMACEUTICALS ANNOUNCES DEVELOPMENT PLAN IN JAPAN FOR GIVINOSTAT FOR DUCHENNE MUSCULAR DYSTROPHY
JCR PHARMACEUTICALS CO LTD: PLAN TO SUBMIT A MARKETING AUTHORIZATION APPLICATION IN JAPAN IN 2026, PRIMARILY USING OVERSEAS CLINICAL DATA
JCR PHARMACEUTICALS CO LTD: PLAN TO OBTAIN APPROVAL AND LAUNCH TREATMENT IN JAPAN IN 2027; AND CONDUCT SEPARATE CLINICAL TRIAL IN JAPANESE PATIENTS WITH DMD TO EVALUATE PHARMACOKINETICS AND SAFETY
Source text: ID:nTSsn90e9f
Further company coverage: 4552.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results